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Abstract : Introduction : The number of patients who undergo laparoscopic sleeve gastrectomy (LSG) has been in-
creasing. Department of Surgery, Tokushima University performed the first LSG in 2013. The aim of this study was 
to report the results of the initial ten cases who underwent a LSG. Patients and methods : Ten obese patients : five 
males and five females ; age range from thirty-three years to fifty-six years (mean age 42.2 years) ; mean body 
mass index (BMI) 50.3 ; five with diabetes ; nine with hypertension (HT) ; four with hyperlipidemia (HL) ; eight 
with sleep apnea syndrome (SAS) who underwent LSG were enrolled in this study. The data was analyzed retro-
spectively and included short- and long-term outcomes. Results : There were no post-operative complications in 
this study. The %EWL at three and six months and one year post-operative were 44.2%, 50.2% and 48.6% respec-
tively. In three months post-operative the non-alcoholic fatty liver (NAFLD) and non-alcoholic steatohepatitis 
(NASH) had improved transaminase (AST/ALT), liver to spleen ratio in plain CT value. Improvements were also 
evident in the obesity-related diseases : diabetes 80% (4/5) ; HT 67% (6/9) ; HL 75% (3/4) ; and SAS 88% (7/8). Conclu-
sion : LSG is a promising option for the treatment of morbid obesity and obesity-related diseases. J. Med. Invest. 
66 : 289-292, August, 2019
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INTRODUCTION
 
Metabolic syndrome (MS) is a disease characterized by obe-
sity, diabetes, hypertension, and dyslipidemia. The incidence of 
MS has increased along with rapid economic development and 
an associated change in diet (1). Consequently, increased atten-
tion has been paid to the prevention of MS. 
There is strong published evidence that bariatric surgery is 
an effective means to sustain long-term weight loss (2-4). Some 
reports have shown that bariatric surgery is superior to internal 
medicine in the treatment of MS (5). Especially, bariatric sur-
gery is reported to achieve complete remission in obese patients 
with type 2 diabetes mellitus (T2DM) (6). 
The authors previously reported that duodenal-jejunal bypass 
improved T2DM and liver steatosis by enhancing glucagon like 
peptide-1 (GLP-1) secretion through increasing serum bile acids 
and the proliferation of L cells in the ileum in vivo (7). 
Three (3) main bariatric surgeries are performed world-
wide : gastric banding ; Roux-en-Y gastric bypass (RYGB) ; and 
sleeve gastrectomy (SG). 
The laparoscopic sleeve gastrectomy (LSG), initially used as 
the first stage of a more complex procedure (duodenal switch or 
gastric bypass) in patients with high surgical risk, has gained 
popularity in recent years due to reported good short-term re-
sults and its relatively lower technical difficulties (8, 9).
In Japan, the number of patients who have undergone a 
LSG has been increasing (10) since the Department of Surgery, 
Tokushima University performed the first LSGs in 2013. These 
initial ten (10) LSG cases are the focus of this study.
MATERIALS AND METHODS
Patient selection and data collection
Patients were included in this study based on the following 
indicators : a LSG at the Tokushima University Hospital ; aged 
between 18 years and 60 years ; a body mass index (BMI) 
of > 35 kg/m2-- ; internal therapy of > 6 months ; and co-morbidity 
with : T2DM ; hypertension (HT) ; hyperlipidemia (HL) ; or sleep 
apnea syndrome (SAS).
The exclusion criteria were : known malignancies ; pregnan-
cy ; and conditions associated with poor compliance (psychiatric 
illness).
The protocol for this research project was approved by a suit-
ably constituted Ethics Committee of the Tokushima University 
Hospital.
From 2013 to 2017, ten (10) patients (5 males and 5 fe-
males ; age range from 33 years to 56 years (mean age 42.2 
years) ; and a mean BMI of 50.3) were referred to the Tokushima 
University for treatment of morbid obesity. Co-morbidity included 
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the following : five (5) patients with T2DM ; nine (9) patients 
with HT ; four (4) patients with HL ; and eight (8) patients with 
SAS (Table 1).
Data were collected retrospectively from medical records and 
supplemented with data and laboratory results. 
Technical description of a LSG
All surgical procedures were started laparoscopically. First, 
the greater curvature and the angle of His were dissected to sta-
ple the gastric fundus and greater curvature parallel to a gastric 
fiber, which was inserted in the stomach through the esophagus. 
Stapling (total five (5) to eight (8) times) was started from a dis-
tance of 5 cm to 8 cm from the pylorus on the greater curvature 
side toward the angle of His. This resulted in a tube-like stomach 
with a volume of approximately 100 mls made from the lesser 
curvature only. The staple line was reinforced by 3-0 PDS and 
vicryl continuous sutures.
Post-operative management 
After the LSGs, the patients were started with water on day 
one (1) post-operative and a liquid diet on days four (4) and five 
(5) post-operative. A thrombosis prophylaxis was administered 
twice a day for a week. 
After discharge, the patients were followed up once a month 
for two (2) months. At outpatient’s clinic, the body weight (BW), 
blood test and plain CT of the patients were evaluated. For the 
purpose of the evaluation for fatty liver, the ratio of liver to spleen 
in plain CT was used. The ratio of liver to spleen in plain CT 
value > 1.0 indicated fatty liver.
Statistical analysis
The t-test was used for statistical analysis of the continuous 
variables. For all tests, p < 0.05 was interpreted as significant. 
The values for each continuous variable were expressed as a 
mean ± the standard deviation (SD).
RESULTS
An overview of the short-term outcomes after the LSGs is 
given in Table 2. The operation time was 233 ± 20.7 minutes 
and the blood loss was 11.7 ± 13.1 ml. The hospital stay after the 
LSGs was 30.8 ± 8.0 days and the weight loss during the hospital 
stay after the LSGs was 16.2 ± 5.8 kg. There were no post-opera-
tive complications after the LSGs. 
Percent excess weight loss (%EWL) in three (3) months, six 
(6) months and one (1) year post-operative were : 44.2% (20.6 – 
56.9) ; 50.2% (32.0 – 61.6) ; and 48.6% (35.5 – 62.6) respectively. 
Obesity related diseases were also improved at one (1) year 
post-operative : diabetes 80% (4/5) ; hypertension 67% (6/9) ; hy-
perlipidemia 75% (3/4) ; and SAS ; 88% (7/8). HbA1c at three (3) 
months post-operative was significantly lower than that record-
ed pre-operation (5.4 vs 6.2) (Table 3).
At three (3) months post-operative the LSGs had decreased 
the value of transaminase (AST/ALT) and increase the ratio of 
liver to spleen in plain CT value. Therefore, the LSGs contrib-
uted to the improvement of non-alcoholic fatty liver (NAFLD)/ 
non-alcoholic steatohepatitis (NASH) (Figures 1a ; 1b ; 1c and 
1d).
 
Table 1.　Patients’ characteristics before LSG. 
Factors n = 10
Age (y.o.) 42.2 (33 – 56)
Gender : male/female 5/5
BW (kg) 138.8 (100.9 – 165.9)
BMI (kg/m2) 50.3 (42.5 – 60.1)
Comorbidity T2DM 5, HT 9, HL 4, SAS 8
HbA1c (%) 6.2 (4.9 – 8.4)
Table 2.　Short-term outcome after LSG.
Factors n = 10
Operation time (min.) 233 ± 20.7
Blood loss (ml) 11.7 ± 13.1
Postoperative complication (%) 0
Hospital stay after LSG (days) 30.8 ± 8.0
Weight loss during hospital stay (kg) 16.2 ± 5.8
Table 3.　Long-term outcome after LSG.
Factors n = 10
%EWL in postoperative 3 months 44.2 (20.6 – 56.9)
%EWL in potoperative 6 months 50.2 (32.0 – 61.6)
%EWL in postoperative 1 year 48.6 (35.5 – 62.6)




HbA1c (%) in postoperative 3 months 5.4 (4.8 – 6.5)
Figures 1a and 1b : The comparison between the pre-operation and 
three (3) months post-operation levels of AST and ALT. The values for 
each continuous variable were expressed as a mean ± the standard de-
viation (SD). The t-test was used for statistical analysis of the continu-
ous variables. For all tests, p < 0.05 was interpreted as significant.
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DISCUSSION
This study was designed to investigate the effect of a LSG on 
obesity and obesity-related disease in the Department of Sur-
gery’s initial ten (10) cases. The results showed not only BW loss 
but also improvements in T2DM, HT, HL, SAS and NAFLD/ 
NASH. 
SG surgery, in which 80% of the stomach is removed along 
the greater curvature but the intestinal anatomy is unaltered, is 
gaining in popularity. A LSG is considered a definitive procedure 
for the treatment of morbid obesity and T2DM. A LSG is increas-
ingly used world-wide and represents the bariatric procedure in 
many countries (11-13). SG is successfully performed by laparos-
copy in 99.7% of cases, with a high leak rate of 1.3%, a low leak 
rate of 0.5% and a mortality rate of 0.1% (14). 
Zhang N, et al. reported that the remission rates of co-morbidi-
ty were observed in LSG for : sleep apnea (91.2) ; hyperlipidemia 
(63%) ; hypertension (38.8%) ; diabetes (58.6%) ; and musculo-
skeletal disease (66.7%) (15). Obesity is associated with NAFLD 
(16), and the resolution of NAFLD following bariatric surgery 
has been proven (17).
Regarding the resolution of diabetes and NASH following a 
LSG, a vertical sleeve gastrectomy (VSG) was reported to be as 
effective as RYGB for increasing secretion of GLP-1 and insulin 
as well as improving hepatic sensitivity to insulin. As well, these 
effects are independent of weight loss (18).
In the author’s previous report, duodenal-jejunal bypass (DJB) 
improved T2DM and liver steatosis by enhancing GLP-1 secre-
tion through increasing serum bile acids and the proliferation of 
L cells in the ileum in vivo (7). In addition, the authors have also 
reported that a DJB changed the composition of gut microbiota 
and these changes might be the factors that contributed to the 
effects of DJB (19). Ryan KK, et al. reported that bile acids and 
bile acid receptor, known as the farnesoid X receptor (FXR) was 
an important molecular underpinning for the beneficial effects of 
bariatric surgery (20). In this report, FXR in SG was associated 
with the change of gut microbiota. So, the important roles in SG 
might be the correlation among bile acids, GLP-1, FXR and gut 
microbiota.
In this study, the initial ten (10) cases who underwent LSGs 
were reported. LSG is a promising option for the treatment of 
morbid obesity and obesity-related disease.
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